EUVIMEDEUVIMED entdecken
Open Access

Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma

Xiangke Xin, Xiaojian Zhu, Yang Yang, Na Wang, Jue Wang, Jinhuan Xu, Jia Wei, Liang Huang, Miao Zheng, Yi Xiao, Chunrui Li, Yang Cao und 3 weitere

Cellular Oncology · 2024

DOI: 10.1007/s13402-024-00940-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2024. Verfasst von Xiangke Xin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National High Technology Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Chimeric antigen receptor (CAR)-T cells obtained long-term durability in about 30% to 40% of relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). Maintenance therapy after CAR-T is necessary, and PD1 inhibitor is one of the important maintenance therapy options. METHODS: A total of 173 r/r B-NHL patients treated with PD1 inhibitor maintenance following CD19/22 CAR-T therapy alone or combined with autologous hematopoietic stem cell transplantation (ASCT) from March 2019 to July 2022 were assessed for eligibility for two trials. There were 81 patients on PD1 inhibitor maintenance therapy. RESULTS: In the CD19/22 CAR-T therapy trial, the PD1 inhibitor maintenance group indicated superior objective response rate (ORR) (82.9% vs 60%; P = 0.04) and 2-year progression-free survival (PFS) (59.8% vs 21.3%; P = 0.001) than the non-maintenance group. The estimated 2-year overall survival (OS) was comparable in the two groups (60.1% vs 45.1%; P = 0.112). No difference was observed in the peak expansion levels of CD19 CAR-T and CD22 CAR-T between the two groups. The persistence time of CD19 and CD22 CAR-T in the PD1 inhibitor maintenance group was longer than that in the non-maintenance group. In the CD19/22 CAR-T therapy combined with ASCT trial, no significant differences in ORR (81.4% vs 84.8%; P = 0.67), 2-year PFS (72.3% vs 74.9%; P = 0.73), and 2-year OS (84.1% vs 80.7%; P = 0.79) were observed between non-maintenance and PD1 inhibitor maintenance therapy groups. The peak expansion levels and duration of CD19 and CD22 CAR-T were not statistically different between the two groups. During maintenance treatment with PD1 inhibitor, all adverse events were manageable. In the multivariable analyses, type and R3m were independent predictive factors influencing the OS of r/r B-NHL with PD1 inhibitor maintenance after CAR-T therapy. CONCLUSION: PD1 inhibitor maintenance following CD19/22 CAR-T therapy obtained superior response and survival in r/r B-NHL, but not in the trial of CD19/22 CAR-T cell therapy combined with ASCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansMaleFemaleMiddle AgedAdultAgedImmune Checkpoint InhibitorsYoung AdultLymphoma, B-CellNeoplasm Recurrence, LocalHematopoietic Stem Cell TransplantationTreatment Outcome

Stichwörter der Autor:innen

Autologous hematopoietic stem cell transplantationB-cell non-Hodgkin-lymphomaChimeric antigen receptor T-cellMaintenance therapyPD1 inhibitor

Substanzen

Programmed Cell Death 1 ReceptorReceptors, Chimeric AntigenImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China.
  • Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, 430030, P. R. China.
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China. 2783084@qq.com.
  • Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, 430030, P. R. China. 2783084@qq.com.
  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China. yczhang@tjh.tjmu.edu.cn.
  • Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, 430030, P. R. China. yczhang@tjh.tjmu.edu.cn.

Förderung

  • National High Technology Research and Development Program

Zitieren

APA

Xin, X., Zhu, X., Yang, Y., Wang, N., Wang, J., Xu, J., Wei, J., Huang, L., Zheng, M., Xiao, Y., Li, C., Cao, Y., Meng, F., Jiang, L., & Zhang, Y. (2024). Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma. Cellular Oncology. https://doi.org/10.1007/s13402-024-00940-y

Vancouver

Xin X, Zhu X, Yang Y, Wang N, Wang J, Xu J, et al. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma. Cellular Oncology. 2024. doi:10.1007/s13402-024-00940-y

BibTeX
@article{Xin2024,
  author = {Xin, Xiangke and Zhu, Xiaojian and Yang, Yang and Wang, Na and Wang, Jue and Xu, Jinhuan and Wei, Jia and Huang, Liang and Zheng, Miao and Xiao, Yi and Li, Chunrui and Cao, Yang and Meng, Fankai and Jiang, Lijun and Zhang, Yicheng},
  title = {Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma},
  journal = {Cellular Oncology},
  year = {2024},
  doi = {10.1007/s13402-024-00940-y}
}
Kostenlos starten →